A recent study on CML patients revealed that deletions of der9 spanning the ABL/BCR breakpoint, and thus abrogating the expression of p40ABL/BCR, were associated with an adverse prognosis [40]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.